SAMSUNG BIOEPIS_2.jpg
Samsung Bioepis Presents Three-year Follow-up Data of Adalimumab Biosimilar SB5 in Patients with Psoriasis at European Academy of Dermatology and Venereology (EADV) Congress
September 07, 2022 02:01 ET | Samsung Bioepis
Long term follow-up data from British Association of Dermatologics and Immunomodulators Register (BADBIR) shows safety and effectiveness of SB5 in patients with psoriasis who have started or...
SAMSUNG BIOEPIS_2.jpg
Samsung Bioepis Presents New Phase 3 Study of SB12 (Eculizumab), A Proposed Biosimilar to Soliris, at the European Hematology Association (EHA) Congress 2022
June 10, 2022 03:01 ET | Samsung Bioepis
Phase 3 study demonstrated clinical equivalence in efficacy, safety, pharmacokinetics (PK), pharmacodynamics (PD), and immunogenicity of SB12 compared to reference eculizumab in paroxysmal nocturnal...
SAMSUNG BIOEPIS_2.jpg
Biogen and Samsung Bioepis’ BYOOVIZ™ (ranibizumab-nuna) Launches in the United States
June 02, 2022 08:00 ET | Samsung Bioepis
BYOOVIZ™ is the first FDA approved ophthalmology biosimilar BYOOVIZ, priced 40% lower than LUCENTIS®, provides an equally effective and more affordable treatment option to patients suffering from...
SAMSUNG BIOEPIS_2.jpg
Samsung Bioepis Announces New Data on Adalimumab Biosimilar, SB5 at the Annual European Congress of Rheumatology (EULAR 2022)
May 31, 2022 18:05 ET | Samsung Bioepis
Samsung Bioepis and Biogen to present one abstract and one poster at EULAR 2022 on adalimumab biosimilar, SB5 including Phase 1 study of a new SB5 formulation and a pan-European real-world study,...
SAMSUNG BIOEPIS_2.jpg
Health Canada Approves Samsung Bioepis and Biogen’s BYOOVIZ™ (SB11), LUCENTIS® Biosimilar (ranibizumab)
March 10, 2022 07:00 ET | Samsung Bioepis
INCHEON, Korea and TORONTO, March 10, 2022 (GLOBE NEWSWIRE) -- Samsung Bioepis Co., Ltd. and Biogen Canada Inc. today announced that Health Canada has approved BYOOVIZ™ – a biosimilar referencing...
SB_10th_Year_Infographic_220228_F
Samsung Bioepis Celebrates 10 Years of Realizing Passion for Health, Innovating Patients Access Worldwide
February 28, 2022 04:40 ET | Samsung Bioepis
Holds a virtual ceremonial event for the first time to mark the anniversary with its global employees Pledges to keep innovating access to biologic medicines worldwide INCHEON, Korea, Feb. 28, 2022...
SAMSUNG BIOEPIS_2.jpg
Samsung Bioepis Announces Health Canada Approval of 150mg Single-use Vial and 440mg Multi-dose Vial of ONTRUZANT® (SB3), Trastuzumab Biosimilar for the Treatment of Adults with Early Breast Cancer, Metastatic Breast Cancer, and Metastatic Gastric Cancer
February 02, 2022 07:00 ET | Samsung Bioepis
150mg and 440mg vial of ONTRUZANT® are now approved in CanadaONTRUZANT® becomes Samsung Bioepis’ fifth biosimilar to be approved in Canada in just six years INCHEON, Korea, Feb. 02, 2022 (GLOBE...
SAMSUNG BIOEPIS_2.jpg
Samsung Bioepis Releases First Annual Sustainability Report
December 21, 2021 05:00 ET | Samsung Bioepis
Outlines the company’s Environment, Social and Governance (ESG) performance and commitment to becoming a socially responsible and sustainable companyAppoints dedicated ESG team to explore and...
SAMSUNG BIOEPIS_2.jpg
Samsung Bioepis’ SB12 Soliris® (Eculizumab) Biosimilar Demonstrates PK, PD Bioequivalence in Phase 1 Study
December 11, 2021 09:00 ET | Samsung Bioepis
Phase 1 study demonstrated pharmacokinetics (PK) equivalence and comparable pharmacodynamic (PD), safety, immunogenicity profiles between SB12 and reference eculizumab INCHEON, Korea, Dec. 11,...
SAMSUNG BIOEPIS_2.jpg
Longest Follow-Up Data on Trastuzumab Biosimilar Presented at 2021 SABCS
December 08, 2021 18:00 ET | Samsung Bioepis
Five-year follow-up results reconfirm comparable long-term efficacy of SB3 (ONTRUZANT®, trastuzumab-dttb) versus Herceptin® through additional analysis with a larger group of patients with...